Share-based Payment Arrangement, Expense of ZyVersa Therapeutics, Inc. from 31 Dec 2021 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
ZyVersa Therapeutics, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2021 to 30 Sep 2025.
  • ZyVersa Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $73,988, a 54% decline year-over-year.
  • ZyVersa Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $366,143, a 56% decline year-over-year.
  • ZyVersa Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $705,567, a 41% decline from 2023.
  • ZyVersa Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $1,192,963, a 66% decline from 2022.
  • ZyVersa Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $3,524,801, a 17% decline from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

ZyVersa Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $366,143 $73,988 -$86,677 -54% 01 Jul 2025 30 Sep 2025 10-Q 19 Nov 2025 2025 Q3
Q2 2025 $452,820 $59,199 -$101,465 -63% 01 Apr 2025 30 Jun 2025 10-Q 13 Aug 2025 2025 Q2
Q1 2025 $554,285 $72,291 -$151,282 -68% 01 Jan 2025 31 Mar 2025 10-Q 12 May 2025 2025 Q1
Q4 2024 $705,567 $160,665 -$136,050 -46% 01 Oct 2024 31 Dec 2024 10-K 27 Mar 2025 2024 FY
Q3 2024 $841,617 $160,665 -$82,380 -34% 01 Jul 2024 30 Sep 2024 10-Q 19 Nov 2025 2025 Q3
Q2 2024 $923,997 $160,664 -$205,078 -56% 01 Apr 2024 30 Jun 2024 10-Q 13 Aug 2025 2025 Q2
Q1 2024 $1,129,075 $223,573 -$63,888 -22% 01 Jan 2024 31 Mar 2024 10-Q 12 May 2025 2025 Q1
Q4 2023 $1,192,963 $296,715 +$240,382 +427% 01 Oct 2023 31 Dec 2023 10-K 27 Mar 2025 2024 FY
Q3 2023 $952,581 $243,045 -$250,977 -51% 01 Jul 2023 30 Sep 2023 10-Q 14 Nov 2024 2024 Q3
Q2 2023 $1,203,558 $365,742 -$330,198 -47% 01 Apr 2023 30 Jun 2023 10-Q 09 Aug 2024 2024 Q2
Q1 2023 $1,533,756 $287,461 01 Jan 2023 31 Mar 2023 10-Q 15 May 2024 2024 Q1
Q4 2022 $56,333 13 Dec 2022 31 Dec 2022 10-K 25 Mar 2024 2023 FY
Q3 2022 $494,022 01 Jul 2022 30 Sep 2022 10-Q 14 Nov 2023 2023 Q3
Q2 2022 $695,940 01 Apr 2022 30 Jun 2022 10-Q 21 Aug 2023 2023 Q2

ZyVersa Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $705,567 -$487,396 -41% 01 Jan 2024 31 Dec 2024 10-K 27 Mar 2025 2024 FY
2023 $1,192,963 -$2,331,838 -66% 01 Jan 2023 31 Dec 2023 10-K 27 Mar 2025 2024 FY
2022 $3,524,801 -$720,662 -17% 01 Jan 2022 12 Dec 2022 10-K 25 Mar 2024 2023 FY
2021 $4,245,463 01 Jan 2021 31 Dec 2021 10-K 31 Mar 2023 2022 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.